ReviewHepatology international2017
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.
Review in Hepatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04493385 (Nationwide Hepatitis C NAT+ Cardiac Transplant Experience), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nationwide Hepatitis C NAT+ Cardiac Transplant Experience
Who cites it
19 citing papers in PubMed.
- FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purineEmerging microbes & infections · 2026Article
- A novelJHEP reports : innovation in hepatology · 2025Article
- Review
- Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).Therapeutics and clinical risk management · 2023Article
- Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings.World journal of hepatology · 2022Review
- Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.Computers in biology and medicine · 2022Article
- Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.PloS one · 2022Article
- The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.ACS medicinal chemistry letters · 2021Article
- Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.Medicine · 2021Observational
- Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.BMC gastroenterology · 2021Article
- Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.BMJ open · 2021Article
- Article
- Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.Acta bio-medica : Atenei Parmensis · 2018Review
- Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.Hepatology international · 2018Review
- The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients.Current transplantation reports · 2018Review
- Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.Viruses · 2017Article
- Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution.Virology journal · 2017Review
- Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.Therapeutics and clinical risk management · 2017Review
- The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment for chronic hepatitis C virus (HCV) has evolved rapidly from an interferon based regimen of modest efficacy with significant adverse events to a well-tolerated, highly effective all-oral directly acting antiviral (DAA) therapy. Although significant improvement in sustained virologic responses (SVR) has been reported with new DAAs for genotypes 1 and 4, effective treatments for genotype 3 have been lacking, and a single pill that can yield high SVR rates against HCV genotypes 1-6 has not been available until now. Sofosbuvir (a pangenotypic NS5B inhibitor) and velpatasvir (a pangenotypic NS5A inhibitor) were recently approved in a fixed-dose combination pill. The availability of this pangenotypic pill holds promise for providing highly effective treatment with minimal laboratory testing for chronic HCV worldwide.
Indexed as
Identifiers
27928718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.